Clinical analyses reveal YTHDF1 is overexpressed in a subset of NPC specimens, with high expression correlating with advanced stage and poor patient outcomes, supporting its potential as a prognostic biomarker. Here, YTHDF1 is linked to nasopharyngeal carcinoma.